Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: Analysis of this patient group revealed that Patient 1 experienced nausea, emesis, anorexia, diarrhea and significant clinical decline during treatment with Aggrenox. Patients 2 and 3 also presented with complaints of nausea and emesis. Lab measurements along with clinical symptoms indicated that all three patients experienced acute renal failure, having increases in serum creatinine of 186%, 144% and 249%, respectively. Symptoms and lab work returned to baseline following discontinuation of Aggrenox. CONCLUSION: It is biologically plausible that Aggrenox may contribute to renal dysfunction in patients under certain pathophysiological circumstances.
|
Authors | Kerry Joy, Sacha Dubois, Carrie Gibbons, John Hargadon, Michel Bédard |
Journal | Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique
(J Popul Ther Clin Pharmacol)
Vol. 17
Issue 2
Pg. e262-8
( 2010)
ISSN: 2561-8741 [Electronic] Australia |
PMID | 20664119
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aspirin, Dipyridamole Drug Combination
- Drug Combinations
- Dipyridamole
- Creatinine
- Aspirin
|
Topics |
- Acute Kidney Injury
(blood, chemically induced, diagnosis)
- Aspirin
(adverse effects)
- Aspirin, Dipyridamole Drug Combination
- Creatinine
(blood)
- Dipyridamole
(adverse effects)
- Drug Combinations
- Humans
|